Neil E. Fleshner
Princess Margaret Hospital
University of Toronto
Toronto
Ontario
Canada
Name/email consistency: high
- Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Fleshner, N.E., Lucia, M.S., Egerdie, B., Aaron, L., Eure, G., Nandy, I., Black, L., Rittmaster, R.S. Lancet (2012)
- Clinical significance of the positive surgical margin based upon location, grade, and stage. Fleshner, N.E., Evans, A., Chadwick, K., Lawrentschuk, N., Zlotta, A. Urol. Oncol. (2010)
- Risk of developing prostate cancer in the future: overview of prognostic biomarkers. Fleshner, N.E., Lawrentschuk, N. Urology (2009)
- Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Fleshner, N., Keane, T.E., Lawton, C.A., Mulders, P.F., Payne, H., Taneja, S.S., Morris, T. Prostate Cancer Prostatic Dis. (2008)
- Prostate cancer prevention: past, present, and future. Fleshner, N., Zlotta, A.R. Cancer (2007)
- Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. Fleshner, N., Harvey, M., Adomat, H., Wood, C., Eberding, A., Hersey, K., Guns, E. J. Urol. (2005)
- Dietary fat and prostate cancer. Fleshner, N., Bagnell, P.S., Klotz, L., Venkateswaran, V. J. Urol. (2004)
- Vitamin E and prostate cancer. Fleshner, N.E. Urol. Clin. North Am. (2002)
- Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer. Fleshner, N.E., Kucuk, O. Urology (2001)
- Diet, androgens, oxidative stress and prostate cancer susceptibility. Fleshner, N.E., Klotz, L.H. Cancer Metastasis Rev. (1998)